A randomized, open label, phase 2 study of the selective inhibitor of nuclear export (sine) selinexor (kpt-330) versus specified physician’s choice in patients ≥ 60 years old with relapsed/refractory acute myeloid leukemia (aml) who are ineligible for int

Cancer type: Leukemia

Phase: II

Principal Investigator: Mølle Ingolf

Country: DK

Keywords: Denmark, Aarhus,

Status: Inclusion completed

Link to